LIVIVO - Search results -

Search results

Result 1 - 10 of total 71

Search options

Article ; Online: A subset of lung adenofibromas are morphological variants of solitary fibrous tumour.

Laville, David / Macagno, Nicolas / Patoir, Arnaud / Mabrut, Marianne / Pissaloux, Daniel / Karanian, Marie / Forest, Fabien

Histopathology

2022 Volume 81, Issue 1, Page(s) 133–137

MeSH term(s)	Adenofibroma ; Humans ; Lung/pathology ; Lung Neoplasms ; Solitary Fibrous Tumors/pathology
Language	English
Publishing date	2022-04-21
Publishing country	England
Document type	Letter
ZDB-ID	131914-0
ISSN	1365-2559 ; 0309-0167
ISSN (online)	1365-2559
ISSN	0309-0167
DOI	10.1111/his.14654
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1328: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Coxal giant cell-rich tumour harbouring an NUTM1 gene fusion: a new molecular subtype of giant cell tumour of bone?

Fattori, Antonin / Reita, Damien / Brinkert, David / Willaume, Thibault / Gantzer, Justine / Karanian, Marie / Lhermitte, Benoit / Wolf, Thibaut / De Pinieux, Gonzague / Weingertner, Noëlle

Histopathology

2024 Volume 84, Issue 6, Page(s) 1072–1075

MeSH term(s)	Humans ; Bone Neoplasms/genetics ; Gene Fusion ; Giant Cell Tumor of Bone/genetics ; Giant Cells ; Neoplasm Proteins/genetics ; Oncogene Proteins, Fusion/genetics ; Transcription Factors/genetics
Chemical Substances	Neoplasm Proteins ; Oncogene Proteins, Fusion ; Transcription Factors
Language	English
Publishing date	2024-01-16
Publishing country	England
Document type	Case Reports ; Letter
ZDB-ID	131914-0
ISSN	1365-2559 ; 0309-0167
ISSN (online)	1365-2559
ISSN	0309-0167
DOI	10.1111/his.15139
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1328: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Soft Tissue Special Issue: Perivascular and Vascular Tumors of the Head and Neck.

Flucke, Uta / Karanian, Marie / Broek, Roel W Ten / Thway, Khin

Head and neck pathology

2020 Volume 14, Issue 1, Page(s) 21–32

Abstract: Perivascular and vascular neoplasms of the head and neck are a rare group of tumors comprising a spectrum of clinical/biologic and histological features. They are frequently diagnostically challenging, due to their morphologic and immunohistochemical ... ...

Abstract	Perivascular and vascular neoplasms of the head and neck are a rare group of tumors comprising a spectrum of clinical/biologic and histological features. They are frequently diagnostically challenging, due to their morphologic and immunohistochemical overlap. In this review, we summarize the pathology of these neoplasms, discussing morphology, immunohistochemistry, associated genetic findings, and the differential diagnoses.
MeSH term(s)	Head and Neck Neoplasms/pathology ; Humans ; Soft Tissue Neoplasms/pathology ; Vascular Neoplasms/pathology
Language	English
Publishing date	2020-01-16
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2407834-7
ISSN	1936-0568 ; 1936-055X
ISSN (online)	1936-0568
ISSN	1936-055X
DOI	10.1007/s12105-020-01129-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: Advances in the classification of round cell sarcomas.

Le Loarer, Francois / Baud, Jessica / Azmani, Rihab / Michot, Audrey / Karanian, Marie / Pissaloux, Daniel

Histopathology

2021 Volume 80, Issue 1, Page(s) 33–53

Abstract: Round cell sarcomas represent a diagnostic challenge for pathologists, owing to the poorly differentiated features of these high-grade tumours. The diagnosis of round cell sarcoma requires large immunohistochemical panels and molecular testing in many ... ...

Abstract	Round cell sarcomas represent a diagnostic challenge for pathologists, owing to the poorly differentiated features of these high-grade tumours. The diagnosis of round cell sarcoma requires large immunohistochemical panels and molecular testing in many cases. This spectrum of malignancies is largely dominated by Ewing sarcomas (ESs), which represent the most common family of these tumours. Nonetheless, new families have been delineated in the past few years, with the addition of two additional families in the 2020 World Health Organization classification of bone and soft tissue tumours, namely sarcomas with CIC rearrangements and sarcomas with BCOR alterations. EWSR1, one of the genes involved in the driver fusion of ESs, is also implicated in the translocation of many other tumours with heterogeneous lineages and variable levels of aggressiveness. Round cell sarcomas associated with fusions inwhichEWSR1is partnered with genes encoding transcription factors distinct from those of the 'Ewing family' represent a heterogeneous group of rare tumours that require further study to determine whether their fusions may or not define a specific subgroup. They include mainly sarcomas with NFATc2 rearrangements and sarcomas with PATZ1 rearrangements. At this point, PATZ1 fusions seem to be associated with tumours of high clinical and morphological heterogeneity. Molecular studies have also helped in the identification of more consistent biomarkers that give tremendous help to pathologists in triaging, if not diagnosing, these tumours in practice. This review compiles the latest accumulated evidence regarding round cell sarcomas, and discusses the areas that are still under investigation.
MeSH term(s)	Biomarkers, Tumor/genetics ; Bone Neoplasms/diagnosis ; Bone Neoplasms/genetics ; Bone Neoplasms/pathology ; Gene Fusion ; Gene Rearrangement ; Humans ; Kruppel-Like Transcription Factors/genetics ; Liposarcoma, Myxoid/diagnosis ; Liposarcoma, Myxoid/genetics ; Liposarcoma, Myxoid/pathology ; NFATC Transcription Factors/genetics ; Repressor Proteins/genetics ; Soft Tissue Neoplasms/diagnosis ; Soft Tissue Neoplasms/genetics ; Soft Tissue Neoplasms/pathology ; Translocation, Genetic
Chemical Substances	Biomarkers, Tumor ; Kruppel-Like Transcription Factors ; NFATC Transcription Factors ; PATZ1 protein, human ; Repressor Proteins
Language	English
Publishing date	2021-12-26
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	131914-0
ISSN	1365-2559 ; 0309-0167
ISSN (online)	1365-2559
ISSN	0309-0167
DOI	10.1111/his.14547
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1328: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Quatrième édition de la classification OMS des tumeurs des tissus mous.

Karanian, Marie / Coindre, Jean-Michel

Annales de pathologie

2015 Volume 35, Issue 1, Page(s) 71–85

Abstract: The new World Health Organization (WHO) classification of soft tissue tumours was published in 2013, 11years after the previous edition. This new classification includes several changes: newly included sections (gastrointestinal stromal tumors…), newly ... ...

Title translation	Fourth edition of WHO classification tumours of soft tissue.
Abstract	The new World Health Organization (WHO) classification of soft tissue tumours was published in 2013, 11years after the previous edition. This new classification includes several changes: newly included sections (gastrointestinal stromal tumors…), newly recognized entities (pseudomiogenic haemangioendothelioma, haemosiderotic fibrolipomatous tumour…), and new genetic and molecular data leading to better understanding and definition of tumours, and are useful as diagnostic tools. This brief review summarizes changes in this new edition of the WHO classification of tumours of soft tissue.
MeSH term(s)	Biomarkers, Tumor ; Cell Differentiation ; Gastrointestinal Stromal Tumors/chemistry ; Gastrointestinal Stromal Tumors/pathology ; Humans ; Neoplasms, Adipose Tissue/chemistry ; Neoplasms, Adipose Tissue/classification ; Neoplasms, Adipose Tissue/pathology ; Nerve Sheath Neoplasms/chemistry ; Nerve Sheath Neoplasms/pathology ; Sarcoma/chemistry ; Sarcoma/classification ; Sarcoma/pathology ; Soft Tissue Neoplasms/chemistry ; Soft Tissue Neoplasms/classification ; Soft Tissue Neoplasms/pathology ; World Health Organization
Chemical Substances	Biomarkers, Tumor
Language	French
Publishing date	2015-01
Publishing country	France
Document type	English Abstract ; Journal Article
ZDB-ID	225720-8
ISSN	0242-6498
ISSN	0242-6498
DOI	10.1016/j.annpat.2014.11.003
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1652: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Dermatofibrosarcoma protuberans, fibrosarcomatous variant: A rare tumor in children.

Chicaud, Matthieu / Frassati-Biaggi, Annonciade / Kaltenbach, Sophie / Karanian, Marie / Orbach, Daniel / Fraitag, Sylvie

Pediatric dermatology

2020 Volume 38, Issue 1, Page(s) 217–222

Abstract: Fibrosarcomatous transformation of dermatofibrosarcoma protuberans is associated with a significantly worse prognosis in adults, but is a very rare feature in the pediatric population. Here, we report a case that occurred in a child. The diagnosis of ... ...

Abstract	Fibrosarcomatous transformation of dermatofibrosarcoma protuberans is associated with a significantly worse prognosis in adults, but is a very rare feature in the pediatric population. Here, we report a case that occurred in a child. The diagnosis of fibrosarcomatous transformation of dermatofibrosarcoma protuberans was confirmed by a histopathological assessment and fluorescence in situ hybridization. A comparison with eleven other patients reported in the literature revealed that the local recurrence and mortality rates in children are similar to those observed in adults.
MeSH term(s)	Adult ; Child ; Dermatofibrosarcoma/diagnosis ; Humans ; In Situ Hybridization, Fluorescence ; Neoplasm Recurrence, Local ; Oncogene Proteins, Fusion/genetics ; Skin Neoplasms
Chemical Substances	Oncogene Proteins, Fusion
Language	English
Publishing date	2020-10-03
Publishing country	United States
Document type	Case Reports
ZDB-ID	605539-4
ISSN	1525-1470 ; 0736-8046
ISSN (online)	1525-1470
ISSN	0736-8046
DOI	10.1111/pde.14393
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1882: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Oral vinorelbine in young patients with desmoid-type fibromatosis.

Kornreich, Laure / Orbach, Daniel / Nicolas, Nayla / Brisse, Hervé J / Berlanga, Pablo / Defachelles, Anne-Sophie / Mansuy, Ludovic / Verite, Cécile / Saumet, Laure / Karanian, Marie / Corradini, Nadège

Tumori

2023 Volume 109, Issue 5, Page(s) 511–518

Abstract: Background: Desmoid-type fibromatosis are rare intermediate tumors in children and adolescents. Owing to local aggressiveness and relapse, systemic treatment for symptomatic advanced or progressive forms is recommended. Following promising results in ... ...

Abstract	Background: Desmoid-type fibromatosis are rare intermediate tumors in children and adolescents. Owing to local aggressiveness and relapse, systemic treatment for symptomatic advanced or progressive forms is recommended. Following promising results in adult patients, oral vinorelbine is investigated in young patients. Methods: A retrospective review of young patients (<25 years old) with advanced or progressive desmoid type fibromatosis treated with oral vinorelbine in eight large centers of the Société Française des Cancers de l'Enfant was performed. In addition to tumor assessment according to RECIST 1.1, pre-treatment and during-treatment imagery were reviewed centrally to assess tumor volume and estimate fibrosis score through the change in percentage in hypoT2 signal intensity. Results: From 2005 to 2020, 24 patients (median age 13.9 years [range, 1.0-23.0]) received oral vinorelbine. Median number of prior systemic lines of treatment was 1 (range, 0-2), mainly based on intravenous low dose methotrexate and vinblastine. Before vinorelbine initiation, all patients had a progressive disease: radiological for 19, radiological and clinical (pain) for three and only clinical for two. Oral vinorelbine was delivered for a median duration of 12 months (range, 1-42). The toxicity profile was favorable, with no grade 3-4 event. Overall response estimated on 23 evaluable patients according to RECIST 1.1 criteria was three partial responses (13%), 18 stabilization (78%) and two progressive disease (9%). Overall progression-free survival was 89.3% (95% confidential intervals 75.2-100) at 24 months. Four stable tumors according to standard RECIST criteria displayed a partial response with > 65% tumor volume reduction. Among 21 informative patients, the estimated fibrosis score decreased for 15 patients, was stable for four patients and increased for two patients. Conclusion: Oral vinorelbine seems to be effective to control advanced or progressive desmoid type fibromatosis in young patients, with a well-tolerated profile. These results support testing this drug as first-line alone or in combination to improve response rate while preserving quality of life.
MeSH term(s)	Adult ; Child ; Adolescent ; Humans ; Vinorelbine ; Fibromatosis, Aggressive/drug therapy ; Quality of Life ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Neoplasm Recurrence, Local/drug therapy ; Vinblastine/therapeutic use ; Fibrosis ; Treatment Outcome
Chemical Substances	Vinorelbine (Q6C979R91Y) ; Vinblastine (5V9KLZ54CY)
Language	English
Publishing date	2023-04-28
Publishing country	United States
Document type	Journal Article
ZDB-ID	280962-x
ISSN	2038-2529 ; 0300-8916
ISSN (online)	2038-2529
ISSN	0300-8916
DOI	10.1177/03008916231169806
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ud II Zs.43: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 287: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: A TLR4 Agonist Induces Osteosarcoma Regression by Inducing an Antitumor Immune Response and Reprogramming M2 Macrophages to M1 Macrophages.

Richert, Iseulys / Berchard, Paul / Abbes, Lhorra / Novikov, Alexey / Chettab, Kamel / Vandermoeten, Alexandra / Dumontet, Charles / Karanian, Marie / Kerzerho, Jerome / Caroff, Martine / Blay, Jean-Yves / Dutour, Aurélie

Cancers

2023 Volume 15, Issue 18

Abstract: Osteosarcoma (OsA) has limited treatment options and stagnant 5-year survival rates. Its immune microenvironment is characterized by a predominance of tumor-associated macrophages (TAMs), whose role in OsA progression remain unclear. Nevertheless, ... ...

Abstract	Osteosarcoma (OsA) has limited treatment options and stagnant 5-year survival rates. Its immune microenvironment is characterized by a predominance of tumor-associated macrophages (TAMs), whose role in OsA progression remain unclear. Nevertheless, immunotherapies aiming to modulate macrophages activation and polarization could be of interest for OsA treatment. In this study, the antitumor effect of a liposome-encapsulated chemically detoxified lipopolysaccharide (Lipo-MP-LPS) was evaluated as a therapeutic approach for OsA. Lipo-MP-LPS is a toll-like receptor 4 (TLR4) agonist sufficiently safe and soluble to be IV administered at effective doses. Lipo-MP-LPS exhibited a significant antitumor response, with tumor regression in 50% of treated animals and delayed tumor progression in the remaining 50%. The agent inhibited tumor growth by 75%, surpassing the efficacy of other immunotherapies tested in OsA. Lipo-MP-LPS modulated OsA's immune microenvironment by favoring the transition of M2 macrophages to M1 phenotype, creating a proinflammatory milieu and facilitating T-cell recruitment and antitumor immune response. Overall, the study demonstrates the potent antitumor effect of Lipo-MP-LPS as monotherapy in an OsA immunocompetent model. Reprogramming macrophages and altering the immune microenvironment likely contribute to the observed tumor control. These findings support the concept of immunomodulatory approaches for the treatment of highly resistant tumors like OsA.
Language	English
Publishing date	2023-09-19
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers15184635
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Using biology to guide the treatment of sarcomas and aggressive connective-tissue tumours.

Dufresne, Armelle / Brahmi, Mehdi / Karanian, Marie / Blay, Jean-Yves

Nature reviews. Clinical oncology

2018 Volume 15, Issue 7, Page(s) 443–458

Abstract: Sarcomas are a heterogeneous group of malignancies that arise from cells of a mesenchymal origin. Surgery forms the mainstay of the treatment of most patients with localized sarcoma and might be followed or preceded by chemotherapy and/or radiotherapy. ... ...

Abstract	Sarcomas are a heterogeneous group of malignancies that arise from cells of a mesenchymal origin. Surgery forms the mainstay of the treatment of most patients with localized sarcoma and might be followed or preceded by chemotherapy and/or radiotherapy. In the metastatic setting, systemic treatments tend to improve survival and control symptoms. However, the adverse events and sometimes disappointing outcomes associated with these empirical approaches to treatment indicate a need for new approaches. The advent of next-generation sequencing (NGS) has enabled more targeted treatment of many malignancies based on the presence of specific alterations. NGS analyses of sarcomas have revealed the presence of many alterations that can be targeted using therapies that are already used in patients with other forms of cancer. In this Review, we describe the genomic alterations considered to define specific nosological subgroups of sarcoma and whose contribution to oncogenesis provides a biological rationale for the use of a specific targeted therapy. We also report several less successful examples that should guide researchers and clinicians to better define the extent to which the identification of driver molecular alterations should influence the development of novel treatments.
MeSH term(s)	Genome, Human/genetics ; Genomic Instability/genetics ; High-Throughput Nucleotide Sequencing ; Humans ; Molecular Targeted Therapy ; Neoplasms, Connective Tissue/genetics ; Neoplasms, Connective Tissue/therapy ; Sarcoma/genetics ; Sarcoma/therapy
Language	English
Publishing date	2018-04-17
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	2491410-1
ISSN	1759-4782 ; 1759-4774
ISSN (online)	1759-4782
ISSN	1759-4774
DOI	10.1038/s41571-018-0012-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6029: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MG 103: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Percutaneous Core Needle Biopsy Can Efficiently and Safely Diagnose Most Primary Bone Tumors.

Crenn, Vincent / Vezole, Léonard / Bouhamama, Amine / Meurgey, Alexandra / Karanian, Marie / Marec-Bérard, Perrine / Gouin, François / Vaz, Gualter

Diagnostics (Basel, Switzerland)

2021 Volume 11, Issue 9

Abstract: A biopsy is a prerequisite for the diagnosis and evaluation of musculoskeletal tumors. It is considered that surgical biopsy provides a more reliable diagnosis because it can obtain more tumor material for pathological analysis. However, it is often ... ...

Abstract	A biopsy is a prerequisite for the diagnosis and evaluation of musculoskeletal tumors. It is considered that surgical biopsy provides a more reliable diagnosis because it can obtain more tumor material for pathological analysis. However, it is often associated with a significant complication rate. Imaging-guided percutaneous core needle biopsy (PCNB) is now widely used as an alternative to surgical biopsy; it appears to be minimally invasive, possibly with lower complication rates. This study evaluates the diagnostic yield of the preferred use of PCNB in a referral center, its accuracy, and its complication rate. The data relating to the biopsy and the histological analysis were extracted from the database of a bone tumor reference center where PCNB of bone tumors was discussed as a first-line option. 196 bone tumors were biopsied percutaneously between 2016 and 2020. They were located in the axial skeleton in 21.4% (42) of cases, in the lower limb in 58.7% (115), and in the upper limb in 19.9% (39) cases. We obtained a diagnosis yield of 84.7% and a diagnosis accuracy of 91.7%. The overall complication rate of the percutaneous biopsies observed was 1.0% (
Language	English
Publishing date	2021-08-27
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2662336-5
ISSN	2075-4418
ISSN	2075-4418
DOI	10.3390/diagnostics11091552
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito